{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-056215","form_type":"8-K","ticker":"ZBIO","cik":"0001953926","company_name":"Zenas BioPharma, Inc.","filed_at":"2025-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.555639+00:00","generated_at":"2026-05-20T00:23:25.153489+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Zenas BioPharma updates pipeline timelines; obexelimab Phase 3 IgG4-RD data due year-end 2025","bullets":["Phase 3 INDIGO trial (IgG4-RD) topline results expected year-end 2025; over 190 patients enrolled.","Phase 2 MoonStone (RMS) primary endpoint (12-week new T1 Gd+ lesions) data expected early Q4 2025.","Phase 2 SunStone (SLE) primary endpoint (24-week BICLA) data expected mid-2026.","Q1 2025 cash of ~$314M; management expects cash runway into Q4 2026.","Prior Phase 2 IgG4-RD showed 93% ongoing response; SLE optimized exposure effect size 35% vs placebo."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-056215","json":"https://secwatch.observer/filing/0001104659-25-056215.json","markdown":"https://secwatch.observer/filing/0001104659-25-056215.md","text":"https://secwatch.observer/filing/0001104659-25-056215.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1953926/000110465925056215/0001104659-25-056215-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1953926/000110465925056215/tm2517068d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T00:23:25.153489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}